Related Experiment Video
Updated: Jun 12, 2025
09:44
Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
Published on: November 27, 2019
10.0K
Adverse Outcome Pathways Mechanistically Describing Hepatotoxicity
Ellen Callewaert1, Jochem Louisse2, Nynke Kramer3,4
1Department of Pharmaceutical and Pharmacological Sciences, Entity of In vitro Toxicology and Dermato-Cosmetology, Vrije Universiteit Brussel, Brussels, Belgium.
Methods in Molecular Biology (Clifton, N.J.)
|September 23, 2024
Summary
Adverse outcome pathways (AOPs) map toxicological processes, aiding computational toxicology and hazard identification for liver toxicity. This chapter reviews AOP development, assessment, and applications in toxicology.
Area of Science:
- Toxicology
- Computational Toxicology
- Molecular Toxicology
Background:
- Adverse outcome pathways (AOPs) link molecular initiating events to adverse outcomes through key events.
- AOPs are valuable tools in computational toxicology for hazard identification.
- Existing AOPs address various forms of hepatotoxicity, including steatosis, cholestasis, fibrosis, and liver cancer.
Purpose of the Study:
- To provide a comprehensive overview of Adverse Outcome Pathways (AOPs) concerning hepatotoxicity.
- To detail the development, assessment, and application of AOPs in toxicological studies.
- To highlight the role of AOPs in advancing in silico prediction models for liver hazard identification.
Main Methods:
- Review of existing literature on Adverse Outcome Pathways (AOPs).
- Analysis of AOP frameworks for hepatotoxicity.
- Discussion of methodologies for AOP development and assessment.
Main Results:
- AOPs offer a structured approach to understanding and predicting liver toxicity.
- The development and assessment of AOPs are crucial for their reliable application.
- AOPs facilitate the design of in silico models for hazard identification.
Conclusions:
- Adverse outcome pathways are essential for understanding hepatotoxicity.
- The application of AOPs in computational toxicology is expanding.
- Further development and assessment of AOPs will enhance toxicological predictions.
Related Concept Videos
01:26Toxic Reactions: Overview
955
When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
955
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
34
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
34
01:17Drug Metabolism: Phase I Reactions
3.2K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
3.2K
01:21Mechanistic Models: Overview of Compartment Models
72
Mechanistic models, a category encompassing both physiological and compartmental modeling, differ from empirical models' approaches to incorporating known factors about the systems being modeled. Empirical models describe data with minimal assumptions, while mechanistic models aim to provide a robust description of available data by specifying assumptions and integrating known factors about the system. Compartmental analysis is a key example of a mechanistic model in pharmacokinetics and...
72
01:19Pharmacovigilance
786
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
786
01:16Drug Biotransformation: Overview
2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K